Infibeam Avenues Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 4, 2025, 1:09 am

Competitors of Infibeam Avenues Ltd

All Competitor Stocks of Infibeam Avenues Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:00 am

Below is a detailed analysis of the quarterly data for Infibeam Avenues Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,280.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,161.00 Cr. (Mar 2025) to 1,280.00 Cr., marking an increase of 119.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,085.00 Cr. (Mar 2025) to 1,209.00 Cr., marking an increase of 124.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 71.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Mar 2025) to 71.00 Cr., marking a decrease of 4.00 Cr..
• For OPM %, as of Jun 2025, the value is 6.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00%.
• For Other Income, as of Jun 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 78.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 1.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Mar 2025) to 26.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Mar 2025) to 58.00 Cr., marking an increase of 3.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.18. The value appears strong and on an upward trend. It has increased from 0.14 (Mar 2025) to 0.18, marking an increase of 0.04.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:07 am

Growth

Last Updated: September 5, 2025, 7:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:26 am

Below is a detailed analysis of the balance sheet data for Infibeam Avenues Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 315.00 Cr.. The value appears strong and on an upward trend. It has increased from 279.00 Cr. (Mar 2025) to 315.00 Cr., marking an increase of 36.00 Cr..
• For Reserves, as of Sep 2025, the value is 3,855.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,457.00 Cr. (Mar 2025) to 3,855.00 Cr., marking an increase of 398.00 Cr..
• For Borrowings, as of Sep 2025, the value is 79.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 172.00 Cr. (Mar 2025) to 79.00 Cr., marking a decrease of 93.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 1,965.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,461.00 Cr. (Mar 2025) to 1,965.00 Cr., marking an increase of 504.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 6,214.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,369.00 Cr. (Mar 2025) to 6,214.00 Cr., marking an increase of 845.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 2,695.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,275.00 Cr. (Mar 2025) to 2,695.00 Cr., marking an increase of 420.00 Cr..
• For CWIP, as of Sep 2025, the value is 140.00 Cr.. The value appears to be declining and may need further review. It has decreased from 448.00 Cr. (Mar 2025) to 140.00 Cr., marking a decrease of 308.00 Cr..
• For Investments, as of Sep 2025, the value is 505.00 Cr.. The value appears strong and on an upward trend. It has increased from 485.00 Cr. (Mar 2025) to 505.00 Cr., marking an increase of 20.00 Cr..
• For Other Assets, as of Sep 2025, the value is 2,873.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,161.00 Cr. (Mar 2025) to 2,873.00 Cr., marking an increase of 712.00 Cr..
• For Total Assets, as of Sep 2025, the value is 6,214.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,369.00 Cr. (Mar 2025) to 6,214.00 Cr., marking an increase of 845.00 Cr..

Notably, the Reserves (3,855.00 Cr.) exceed the Borrowings (79.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Infibeam Avenues Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 5. It has increased from 0.57 (Mar 24) to 0.85, marking an increase of 0.28.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has increased from 0.56 (Mar 24) to 0.84, marking an increase of 0.28.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 3. It has increased from 0.81 (Mar 24) to 1.08, marking an increase of 0.27.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 13.39. It has increased from 12.42 (Mar 24) to 13.39, marking an increase of 0.97.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 13.39. It has increased from 12.42 (Mar 24) to 13.39, marking an increase of 0.97.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.31. It has increased from 11.40 (Mar 24) to 14.31, marking an increase of 2.91.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 2. It has increased from 1.01 (Mar 24) to 1.35, marking an increase of 0.34.
• For PBIT / Share (Rs.), as of Mar 25, the value is 1.10. This value is within the healthy range. It has increased from 0.76 (Mar 24) to 1.10, marking an increase of 0.34.
• For PBT / Share (Rs.), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.75 (Mar 24) to 1.08, marking an increase of 0.33.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 2. It has increased from 0.56 (Mar 24) to 0.82, marking an increase of 0.26.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 2. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
• For PBDIT Margin (%), as of Mar 25, the value is 9.43. This value is below the healthy minimum of 10. It has increased from 8.85 (Mar 24) to 9.43, marking an increase of 0.58.
• For PBIT Margin (%), as of Mar 25, the value is 7.66. This value is below the healthy minimum of 10. It has increased from 6.68 (Mar 24) to 7.66, marking an increase of 0.98.
• For PBT Margin (%), as of Mar 25, the value is 7.56. This value is below the healthy minimum of 10. It has increased from 6.60 (Mar 24) to 7.56, marking an increase of 0.96.
• For Net Profit Margin (%), as of Mar 25, the value is 5.75. This value is within the healthy range. It has increased from 4.98 (Mar 24) to 5.75, marking an increase of 0.77.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.64. This value is below the healthy minimum of 8. It has increased from 4.98 (Mar 24) to 5.64, marking an increase of 0.66.
• For Return on Networth / Equity (%), as of Mar 25, the value is 6.03. This value is below the healthy minimum of 15. It has increased from 4.57 (Mar 24) to 6.03, marking an increase of 1.46.
• For Return on Capital Employeed (%), as of Mar 25, the value is 7.30. This value is below the healthy minimum of 10. It has increased from 5.68 (Mar 24) to 7.30, marking an increase of 1.62.
• For Return On Assets (%), as of Mar 25, the value is 4.19. This value is below the healthy minimum of 5. It has increased from 3.03 (Mar 24) to 4.19, marking an increase of 1.16.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.68 (Mar 24) to 0.75, marking an increase of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has increased from 1.39 (Mar 24) to 1.59, marking an increase of 0.20.
• For Quick Ratio (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has increased from 1.39 (Mar 24) to 1.59, marking an increase of 0.20.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.44 (Mar 24) to 0.00, marking a decrease of 8.44.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 5.88 (Mar 24) to 0.00, marking a decrease of 5.88.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.56 (Mar 24) to 0.00, marking a decrease of 91.56.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 94.12 (Mar 24) to 0.00, marking a decrease of 94.12.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 45.48. This value is within the healthy range. It has decreased from 118.41 (Mar 24) to 45.48, marking a decrease of 72.93.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 28.26. This value is within the healthy range. It has decreased from 67.63 (Mar 24) to 28.26, marking a decrease of 39.37.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,551.55. It has decreased from 8,854.22 (Mar 24) to 4,551.55, marking a decrease of 4,302.67.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.14. This value is within the healthy range. It has decreased from 2.79 (Mar 24) to 1.14, marking a decrease of 1.65.
• For EV / EBITDA (X), as of Mar 25, the value is 12.09. This value is within the healthy range. It has decreased from 31.54 (Mar 24) to 12.09, marking a decrease of 19.45.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has decreased from 2.99 (Mar 24) to 1.16, marking a decrease of 1.83.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 91.55 (Mar 24) to 0.00, marking a decrease of 91.55.
• For Price / BV (X), as of Mar 25, the value is 1.24. This value is within the healthy range. It has decreased from 2.75 (Mar 24) to 1.24, marking a decrease of 1.51.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has decreased from 2.99 (Mar 24) to 1.16, marking a decrease of 1.83.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness